← All trials
NCT06254469
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2026
- First posted
- Feb 12, 2024
- Last posted
- Feb 12, 2024
- Enrollment
- 230
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CereMark Pharma, LLCLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.